- Home
- SPB vs AKRO Comparison
SPB vs AKRO Comparison
Compare SPB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPB
- AKRO
- Stock Information
- Founded
- SPB 1906
- AKRO 2017
- Country
- SPB United States
- AKRO United States
- Employees
- SPB N/A
- AKRO N/A
- Industry
- SPB Industrial Machinery/Components
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SPB Miscellaneous
- AKRO Health Care
- Exchange
- SPB Nasdaq
- AKRO Nasdaq
- Market Cap
- SPB 2.5B
- AKRO 2.4B
- IPO Year
- SPB N/A
- AKRO 2019
- Fundamental
- Price
- SPB $90.26
- AKRO $31.20
- Analyst Decision
- SPB Buy
- AKRO Strong Buy
- Analyst Count
- SPB 7
- AKRO 8
- Target Price
- SPB $101.71
- AKRO $46.83
- AVG Volume (30 Days)
- SPB 327.5K
- AKRO 673.4K
- Earning Date
- SPB 11-15-2024
- AKRO 11-08-2024
- Dividend Yield
- SPB 1.88%
- AKRO N/A
- EPS Growth
- SPB N/A
- AKRO N/A
- EPS
- SPB 4.10
- AKRO N/A
- Revenue
- SPB $2,963,900,000.00
- AKRO N/A
- Revenue This Year
- SPB $1.96
- AKRO N/A
- Revenue Next Year
- SPB $1.85
- AKRO N/A
- P/E Ratio
- SPB $21.87
- AKRO N/A
- Revenue Growth
- SPB 1.55
- AKRO N/A
- 52 Week Low
- SPB $65.50
- AKRO $15.32
- 52 Week High
- SPB $96.74
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- SPB 47.32
- AKRO 51.61
- Support Level
- SPB $85.44
- AKRO $27.05
- Resistance Level
- SPB $91.45
- AKRO $31.60
- Average True Range (ATR)
- SPB 2.53
- AKRO 1.87
- MACD
- SPB -0.27
- AKRO -0.33
- Stochastic Oscillator
- SPB 47.07
- AKRO 47.03
About SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, global Pet Care, Home and Garden. The Company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.